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Motor symptoms in Parkinson’s disease (PD) are tightly linked to the degeneration of
substantia nigra dopaminergic neurons and their projections into the striatum. Moreover,
a broad range of non-motor symptoms like anxiety and depression frequently occur
in PD, most likely related to the loss of serotonergic neurons and their projections
into corresponding target regions. Strikingly, nigral dopaminergic neurons and raphe
serotonergic neurons are severely affected in PD showing characteristic hallmarks of
PD neuropathology, in particular alpha-synuclein containing Lewy bodies and Lewy
neurites. So far, the initial events underlying neurodegenerative processes in PD are not
well understood. Several observations, however, indicate that neurites and synapses of
diseased neurons may be the first subcellular compartments compromised by alpha-
synuclein associated pathology. In particular axonal pathology and deficits in axonal
transport may be leading to the onset of synucleinopathies such as PD. This review
will highlight current findings derived from imaging and neuropathological studies in PD
patients, as well as cellular and animal PD models, which define the initial underlying
structural and molecular events within dopaminergic and serotonergic circuits leading
to the ‘dying back’ degeneration of axonal projections in PD.
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INTRODUCTION
Parkinson’s disease (PD) represents the second most common neurodegenerative disorder,
affecting up to ten million people worldwide (de Lau and Breteler, 2006), with a predicted increase
of more than twofold by 2030 (Dorsey et al., 2007). PD patients show progressive motor symptoms
such as bradykinesia, rigidity, and resting tremor. Moreover, PD is accompanied by a broad
range of non-motor symptoms (NMS), including cognitive deficits, autonomic dysfunctions, and
mood disorders (Marras and Chaudhuri, 2016). While the etiology of PD still remains unclear,
the aggregation of the presynaptic protein alpha-synuclein, either within Lewy bodies or Lewy
neurites of susceptible neurons is of ultimate diagnostic value (Dickson et al., 2009). The other
major neuropathological hallmark of PD is the degeneration and subsequent loss of dopaminergic
neurons in the substantia nigra (SN) leading to prototypic motor deficits (Greffard et al., 2006).
Interestingly, Lewy pathology was also described in numerous other neuronal subpopulations in
distinct brain regions, most likely occurring even prior to dopaminergic SN neurons, e.g., in the
medulla oblongata, olfactory bulb, and pontine tegmentum (Braak et al., 2003). These findings are
paralleled by deficits of several neurotransmitter systems including serotonergic, noradrenergic,
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cholinergic, GABAergic, and glutamatergic signaling (reviewed
in Brichta et al., 2013). PD pathology in these non-dopaminergic
systems, in particular serotonergic neurotransmission, may be
related to NMS like anhedonia, anxiety and depression, affecting
up to 50% of PD patients and having a strong impact on patients’
quality of life (Gallagher and Schrag, 2012; Duncan et al., 2014;
Bugalho et al., 2016).
Several studies imply that dysfunction of different
neurotransmitter systems occur even prior to the presence
of Lewy pathology and the consequent neuronal loss [e.g.,
reviewed in (Burke and O’Malley, 2013)]. This led to the overall
hypothesis, that the main pathophysiological process is related to
a “dying back” of axons prior to the loss of neuronal perikarya
(Hornykiewicz, 1998; Cheng et al., 2010). This review will discuss
recent findings of clinical and neuropathological studies, as
well as molecular mechanisms from cellular and animal models
supporting the concept of an early axonal pathology in PD.
LOSS OF DOPAMINERGIC NEURONS
AND THEIR PROJECTIONS IN PD
The involvement of the nigrostriatal dopaminergic system in
PD was noted as early as neuropathological studies detected
the loss of melanin-containing dopaminergic neurons in the
SN of affected patients (Pakkenberg and Brody, 1965; Hirsch
et al., 1988). The extent of neuronal loss in the SN by the time
of clinical diagnosis was subject of several subsequent studies:
While many reviews repeatedly state that first motor symptoms
appear after 50% of SN dopaminergic neurons are lost (Lang
and Lozano, 1998; Nandhagopal et al., 2008), comprehensive
clinico-neuropathological studies used regression analysis to
more precisely determine the loss of dopaminergic neurons at the
time of symptom onset. Fearnley and Lees (1991) estimated the
percentage of lost pigmented SN neurons at symptom onset by
31%. Subsequent stereological analyses provided similar results
extrapolating the number of remaining pigmented SN neurons to
the time of motor symptom onset to about 70% (Ma et al., 1997;
Greffard et al., 2006). In summary, neuropathological-clinical
correlations suggest that initial motor signs in PD occur as early
as around 30% of total SN neurons are lost.
In contrast, the loss of dopaminergic striatal nerve terminals at
motor symptoms onset is rather difficult to determine: An early
neurochemical study focused on caudate dopamine levels in post-
mortem tissue in two different cohorts (about 60 years vs. 73 years
of age), and allowed an extrapolation to the time of symptom
onset ranging from 68 to 82% of dopamine reduction (Riederer
and Wuketich, 1976). To circumvent the concerns about post-
mortem delay, another study utilized measurement of vesicular
monoamine transporter (VMAT2) binding with tritiated alpha-
dihydrotetrabenazine ([3H]TBZOH) in post-mortem caudate
from PD patients with different disease duration (Scherman et al.,
1989). Here, the regression analysis indicated a loss of 49% of
binding sites by the time of motor symptom onset. In general, the
loss of dopamine terminals is higher in the putamen compared
to the caudate (Kish et al., 1988), allowing the assumption that
the loss of binding in the putamen ranges even higher than 50%
by the time of onset of motor symptoms. Recently, Kordower
et al. (2013) described in detail the integrity of nigrostriatal
dopaminergic connectivity using tyrosine hydroxylase (TH)
and dopamine transporter (DAT) as markers for dopaminergic
function: In PD, dopaminergic fiber density in the dorsal
putamen was rapidly and severely decreased leading to a virtually
complete neuritic loss at 4 years after the clinical diagnosis
compared to controls. In contrast, TH+ SN neurons were less
severely affected from the earliest time points on, with a minor
loss over time, resulting in a residual population of dopaminergic
neurons even decades after diagnosis (Kordower et al., 2013).
In another study, this group detected an early loss of kinesin
protein (anterograde transport motor protein) in the putamen
of PD patients (H&Y stage 1 and 2), representing axonal loss,
while reductions of typical cytoplasmic proteins like dynein light
chain Tctex 3 as well as TH protein levels in the SN were only
observed at later PD stages (Chu et al., 2012). Taken together,
these observations support the hypothesis of an early axonal
degeneration involving transport deficits in PD.
IMPAIRED NIGROSTRIATAL
DOPAMINERGIC PROJECTIONS IN VIVO
While there are concerns about the significance of neuro-
pathological and -chemical measures due to post-mortem delay,
several in vivo studies investigated axonal or synaptic loss by
using radioligand imaging (reviewed recently by Politis, 2014),
in particular measuring DAT and VMAT2 (Table 1). Again,
particularly those studies performing regression analysis to the
onset of motor symptoms are relevant: the proportion of lost
striatal and putaminal dopaminergic terminals was estimated
up to 56% (Schwartz et al., 2004). Using [123I]beta-CIT SPECT
to label presynaptic DAT an early study described a loss of
dopaminergic terminals contralateral to the unaffected side by
39–51% in the striatum and 51–64% in the putamen (Tissingh
et al., 1998). In a larger study using two different PET markers,
for DAT and VMAT2, the loss of putaminal dopaminergic
innervation was between 51 and 71% for both tracers (Lee et al.,
2000). More recent work using these established PET markers
suggests that younger PD patients are able to compensate over
several years the progressive dysfunction of the dopaminergic
system before the first motor symptoms are recognized (de la
Fuente-Fernandez et al., 2011).
At present, neuro-pathological and -imaging findings suggest
that at the onset of motor symptoms in PD the loss of striatal
or putaminal dopaminergic projections largely exceeds that of
dopaminergic SN neurons, again supporting the hypothesis of
a “dying back” of axons to their dopaminergic perikarya in PD
(Cheng et al., 2010; Chu et al., 2012; Burke and O’Malley, 2013).
LOSS OF SEROTONERGIC NEURONS
AND THEIR PROJECTIONS IN PD
Serotonergic neurotransmission is widely distributed
in the brain and mediated by serotonergic neurons in
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TABLE 1 | Parkinson’s disease (PD) imaging studies of dopaminergic and serotonergic deficits.
Modality Method Ligand N Region Marker loss (%) Type of analysis Reference
Dopamine imaging
DAT binding SPECT [123 I]- IPT 6 Striatum 43 Regression to time of
symptom onset
Schwartz et al., 2004
Putamen 56
SPECT [123 I]- β-CIT 8 (H&Y I) Striatum 39–51 H&Y I (ipsi- vs. contralateral) Tissingh et al., 1998
Putamen 51–64
PET [11C]- MP 13 (H&Y I) Putamen 56–71 H&Y I (ipsi- vs. contralateral) Lee et al., 2000
VMAT2 binding PET [11C]- DTBZ 13 (H&Y I) Putamen 51–62 H&Y I (ipsi- vs. contralateral) Lee et al., 2000
PET [11C]- DTBZ 78 (H&Y I-II) Putamen 71 (younger)
34 (older)
Regression to time of
symptom onset; younger
vs. older age of onset
de la Fuente-Fernandez
et al., 2011
Serotonin imaging
SERT binding PET [11C]McN5652 13 Caudate 50 H&Y I-IV vs. controls Kerenyi et al., 2003
Putamen 35
PET [11C]- DASB 9 Caudate 30 H&Y II-III vs. controls Guttman et al., 2007
Putamen 26
Midbrain 29
Orbitofrontal cortex 22
PET [11C]- DASB 5 Forebrain regions 40–50 H&Y I-II,5 vs. controls Albin et al., 2008
Caudal brain stem
regions
∼20
PET [11C]- DASB 30 Caudate 28 H&Y I-II vs. controls Politis et al., 2010
Thalamus 17
Anterior cingulate
cortex
32
+ Putamen 33 H&Y II-III vs. controls
+ Prefrontal cortex 40
+ Raphe nuclei 19/22 H&Y III-IV vs. controls
+ Amygdala 25
PET [11C]- DASB 30 Ventral striatum
Anterior cingulate cortex
Caudate (R)
Orbitofrontal cortex (R)
Significant loss Apathetic vs. non-apathetic
drug naïve early PD
Maillet et al., 2016
IPT, N-(3-iodopropen-2-yl)-2beta-carboxymethoxy-3beta-(4-chlorophenyl)-tropane; β-CIT, beta-carbomethoxy-3 beta-(4-iodophenyltropane); MP, methylphenidate;
DTBZ, dihydrotetrabenazine; McN5652, (l,2,3,5,6,10βhexahydro6[4(methylthio) phenyl] pyrrolo[2,1-a]isoquinoline); DASB, 3-amino-4-(2-dimethylaminomethyl-
phenylsufanyl-)benzonitrile.
the raphe nuclei (RN). Clusters of rostral RN neurons
mainly project to the forebrain innervating basal ganglia,
amygdala, hippocampus, hypothalamus, and several
cortical regions (Parent et al., 2011; Wallman et al., 2011).
Important functions are linked to the serotonergic system
including motor function, as well as cognition and mood:
Dysfunction of serotonin (5-hydroxytryptamine, 5-HT)
neurotransmission contributes to resting tremor and
levodopa-induced dyskinesias (Doder et al., 2003; Rylander
et al., 2010; Politis et al., 2014) as well as to typical
NMS of PD, in particular apathy, anxiety, anhedonia,
and depression (Pavese et al., 2010; Ballanger et al.,
2012).
Neuropathological analyses demonstrated an early
involvement of serotonergic neurons in PD (Halliday et al.,
1990; Paulus and Jellinger, 1991), associated with the presence
of Lewy pathology within the RN at an early disease stage (Braak
et al., 2003; Seidel et al., 2015). In detail, work by Halliday
et al. (1990) described a loss of serotonergic neurons in the
median RN of PD patients by 56%. Intriguingly, serotonergic
cell loss was correlated with depression in PD, revealing
an increased cell loss in the RN of depressed PD patients
(Paulus and Jellinger, 1991). Typical NMS, possibly related to
the serotonergic system like anxiety or depression, are often
present before the onset of motor symptoms (Weintraub
et al., 2015). Moreover, serotonin depletion was observed
in several target regions of the RN including basal ganglia,
hypothalamus, hippocampus, and prefrontal cortex (Fahn
et al., 1971; Shannak et al., 1994). In addition, levels of
serotonin transporter (SERT) immunoreactivity, protein
levels of tryptophan hydroxylase, 5-HT and its metabolites
were reduced in the caudate nucleus compared to the
putamen in post-mortem tissue from PD patients (Kish et al.,
2008).
Frontiers in Cellular Neuroscience | www.frontiersin.org 3 December 2016 | Volume 10 | Article 293
fncel-10-00293 December 20, 2016 Time: 14:59 # 4
Grosch et al. Axonal Degeneration in PD
IN VIVO STUDIES ADDRESSING THE
SEROTONERGIC SYSTEM IN PD
Specific radioligands for the serotonergic system allowed new
insights in PD related alterations in vivo (Table 1): Besides
selective radiotracers for 5-HT receptors, particularly the highly
selective detection of SERT using [11C]-DASB PET enabled
tracing of serotonergic terminals in the brain. Early studies
detected a reduced SERT binding in the caudate nucleus and
the putamen of PD patients (Kerenyi et al., 2003; Guttman
et al., 2007). A follow-up study stratified for disease duration
and without history of depression, described in detail an
early loss of serotonergic terminals in the caudate nucleus,
thalamus, hypothalamus, and anterior cingulum, followed by
further deficits in putamen, insula, posterior cingulum, and
prefrontal cortex in PD (Politis et al., 2010). Interestingly, the
loss of SERT binding in the caudal and rostral RN occurred
in advanced disease stages only, which points to an earlier
affection of serotonergic projections compared to serotonergic
neurons. This notion was supported by another [11C]-DASB-
PET study showing reduced forebrain, but preserved brain stem
SERT binding in PD patients (Albin et al., 2008). Interestingly,
a recent PET study in PD patients without signs of apathy
mainly showed dopaminergic denervation, while serotonergic
innervation remained preserved. In contrast, PD patients with
apathy exhibited additional serotonergic loss within the right
caudate, insula, orbitofrontal cortex, and cingulum without
prominent dopaminergic deficits (Maillet et al., 2016). Despite
these new insights into the dysfunction of the serotonergic
system in PD, a temporal dissociation of the loss of serotonergic
terminals in the forebrain and the number of RN neurons has not
been well established, although these imaging studies point to an
early degeneration of serotonergic nerve terminals.
AXONAL DEGENERATION IN MURINE
PD MODELS
In order to get a more precise insight into the temporal pattern of
degenerative events, several animal as well as cellular models are
relevant:
Numerous transgenic animal models for PD have been
generated, mostly carrying mutations in genes associated with
monogenic PD such as alpha-synuclein, leucine rich repeat kinase
2 (LRRK2), Parkin, PTEN-induced putative kinase 1 (PINK1),
and protein deglycase DJ-1 (reviewed by Lee et al., 2012).
Longitudinal studies provide important information about the
temporal progression of neurodegenerative events within the
dopaminergic system (Figure 1).
Chung et al. (2009) injected adeno-associated virus (AAV)
2 encoding for human A53T alpha-synuclein into the SN of
rats. After 4 weeks, dopaminergic axons within the striatum
were dystrophic and swollen, and levels of dynein, mediating
retrograde axonal transport, were significantly decreased. Eight
weeks after AAV injection, several microtubule based motor
proteins required for anterograde transport were reduced in
the striatum. Since these findings were not observed in the
SN, an initial impairment of dopaminergic axons is implied.
BAC alpha-synuclein transgenic mice, expressing human alpha-
synuclein had a reduced striatal dopamine release without a loss
of dopaminergic SN neurons at 3 months of age (Janezic et al.,
2013). In contrast, the number of dopaminergic SN neurons was
significantly reduced in aged (18-month-old) mice accompanied
by a motor phenotype. This temporal pattern of structural and
functional measures indicated an early axonal phenotype prior
to the loss of SN perikarya. Using another BAC alpha-synuclein
construct, an increased DAT level in whole brain lysates without
reduction of dopaminergic SN neurons was observed in 24-
month-old mice (Yamakado et al., 2012). BAC transgenic rats
overexpressing full-length human alpha-synuclein show a severe
motor impairment at 12 months of age with severe striatal
dopamine depletion. Importantly, TH+ striatal fibers and TH+
SN neurons were reduced in 18-month-old rat, but not in 3-
month-old rat (Nuber et al., 2013).
While there was already some evidence for the onset of
PD pathology within projection areas of dopaminergic neurons,
recent animal studies revealed a similar temporal pattern of
events within the serotonergic system of murine PD models
(Figure 1).
Aforementioned BAC transgenic rats (published by
Nuber et al., 2013) additionally display severe impairment
of hippocampal neurogenesis, a feature strongly associated
with early behavioral phenotypes like depression and anxiety at
4 months of age, even prior to the onset of a motor phenotype
(Kohl et al., 2016). Impaired hippocampal neurogenesis was
accompanied by a profoundly reduced serotonergic innervation
of the hippocampal dentate gyrus (DG; Kohl et al., 2016).
Furthermore, 5-HT receptor expression was altered and 5-
HT levels were significantly reduced in the hippocampal DG
and CA3 region of transgenic animals, strongly indicating an
early dysfunction of serotonergic terminals. The number of
serotonergic neurons in the RN, however, remained unaltered.
This temporal pattern of structural changes and the functional
phenotype in the BAC transgenic rat model demonstrates that
an early axonal phenotype preceding the loss of perikarya is
also present in the serotonergic system in PD. Further evidence
for an early axonal phenotype within the serotonergic system
derives from the A53T alpha-synuclein mouse model (A53T
mice) of PD. At 52 weeks of age, human synuclein was expressed
in serotonergic RN neurons and their projections within the
hippocampal formation (Deusser et al., 2015). While the number
of serotonergic neurons was preserved in A53T mice, the density
of serotonergic fibers within the dorsal DG was severely reduced.
Furthermore, viral injections allowing the overexpression of
alpha-synuclein selectively in serotonergic neurons resulted in a
progressive degeneration of serotonergic axon terminals in the
hippocampus, while the number of serotonergic RN neurons
remained unaltered (Wan et al., 2016). Mutations in PINK1
are linked to monogenic forms of PD, as well. PINK1 deficient
mice showed no motor phenotypes, but olfactory deficits at
19 months of age (Glasl et al., 2012). Olfactory dysfunction
is a very common NMS in PD. Interestingly, serotonergic
innervation was significantly diminished in the glomerular layer
of the olfactory bulb, while again there was no reduction in the
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FIGURE 1 | (A) Loss of dopaminergic terminals (stained for tyrosine hydroxylase, TH) in the striatum precedes loss of substantia nigra pars compacta (SNpc)
dopaminergic neurons in transgenic mouse models of PD. (B) While the number of serotonergic neurons within the medium raphe nuclei (mRN) was not changed in
different transgenic mouse models of PD, the innervation of the hippocampal formation (stained for serotonin transporter, SERT) and the glomerular layer of the
olfactory bulb was diminished together with depressive symptoms and impaired olfaction, respectively.
numbers of serotonergic RN neurons. This study also strongly
indicates an early loss of serotonergic terminals in a second target
region besides the hippocampal formation associated with NMS
in PD.
Besides transgenic PD models acute neurotoxic models using
toxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) or 6-hydroxydopamine (6-OHDA) specifically target
dopaminergic SN neurons (reviewed by Blandini and Armentero,
2012). 6-OHDA is commonly injected directly into the
striatum or the medial forebrain bundle, thereby directly
damaging dopaminergic terminals. Few studies applied unilateral
intranigral injections and revealed a severe loss of TH+ neurons
associated with a severe reduction of dopaminergic fibers (Moses
et al., 2008; Grealish et al., 2010). For systemic application of
MPTP which specifically diminishes dopaminergic neurons a
severe loss of TH+ striatal fibers was observed, but the temporal
pattern of these events was not analyzed in detail. One day after
MPTP treatment Serra et al. detected a 60% reduction of striatal
dopaminergic fibers without significant increase in apoptotic
TUNEL positive cells within the SN (Serra et al., 2002).
NEURITE DEGENERATION IN HUMAN
STEM CELL MODELS OF PD
The opportunity to model PD by reprogramming patient
derived cells into induced pluripotent stem cells (iPSC)
and differentiating them into neurons recently advanced
the availability of human cellular models of PD. Human
dopaminergic neurons of sporadic and LRRK2 PD patients
(carrying the G2019S mutation) showed markedly less neurites
per dopaminergic neuron and shorter neurites in both patient
cohorts after 75 days of neuronal differentiation. The number of
caspase3 positive cells, however, was also significantly increased
in patient derived neurons pointing toward higher rates of
cell death in these cultures. The neuritic phenotype appeared
rather simultaneously to the degeneration of the dopaminergic
neurons in this iPSC derived PD model. Using another
approach to generate dopaminergic neurons from LRRK2 patient
derived iPSC carrying the identical G2019S mutation, Borgs
et al. (2016) detected a different phenotype. LRRK2 patient
derived neurons that were generated from neural progenitor
cells using small molecules showed a reduced total neurite
length and increased neurite branching while the number
of TH positive neurons was not altered after 35 days of
differentiation.
CONCLUDING REMARKS/
PERSPECTIVES
Enormous progress in imaging techniques, a large variety of
animal models and the availability of PD patient iPSC derived
Frontiers in Cellular Neuroscience | www.frontiersin.org 5 December 2016 | Volume 10 | Article 293
fncel-10-00293 December 20, 2016 Time: 14:59 # 6
Grosch et al. Axonal Degeneration in PD
neurons helped to significantly improve our knowledge of the
temporal pattern of pathomechanisms underlying PD. Given
the early appearance of NMS in PD and their tremendous
impact on the patients’ quality of life it is important to compare
the timeline of pathogenic events within the serotonergic
system with those more soundly explored in the dopaminergic
system. One important recent milestone in PD research
represents the appreciation that the onset of the disease
may take place at the synaptic site and within the axonal
compartment. Another milestone in PD research is the focus
on other neurotransmitter systems besides dopamine, since
especially early phenotypes of PD are strongly associated
with e.g., alterations of the serotonergic system. One possible
mechanism underlying axonal degeneration in PD may be the
impairment of axonal transport due to protein aggregation,
cytoskeleton instability, or motor protein dysregulation (Lee
et al., 2006; Esteves et al., 2010; Volpicelli-Daley et al.,
2014). Whether protein aggregation within the axon, motor
protein dysfunction, or disturbance of motor protein binding
to microtubules initiates the impairment of axonal transport
remains to be elucidated. Another initial mechanism may be
the reorganization of the synapse including altered availability
of neurotransmitter receptors and transporters. Focusing on the
mechanisms of axonal degeneration both in the dopaminergic
and the serotonergic system or potentially even inducing axonal
regeneration may be a very promising strategy to intervene at a
very early stage with disease progression.
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